Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04614103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites reduced: 91 → 71 locationsv27
  2. Study sites: 84 to 91v26
  3. Study sites: 64 to 84v25
  4. Study sites: 60 to 64v24
  5. Study sites: 49 to 60v23
Show 21 earlier versionsHide 21 earlier versions
  1. Study sites: 44 to 49v22
  2. Site details revised at 1 of 44 sitesv21
  3. Primary completion date: Jun 2024 to Dec 2030 Study sites: 42 to 44 · Completion date: Dec 2026 to Dec 2031 · Eligibility criteria revisedv20 Show 3 more changesShow less
    • Study sites: 42 to 44
    • Completion date: Dec 2026 to Dec 2031
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  4. Site details revised at 2 of 42 sitesv19
  5. Enrollment target: 95 to 170 Study sites: 41 to 42 · Study arms: 4 to 5 · Eligibility criteria expanded, about 2 wordsv18 Show 3 more changesShow less
    • Study sites: 41 to 42
    • Study arms: 4 to 5
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  6. Site details revised at 2 of 41 sitesv17
  7. Site details revised at 4 of 41 sitesv16
  8. Study sites: 38 to 41 Eligibility criteria expanded, about 19 wordsv15 Show 1 more changeShow less
    • Eligibility criteria expanded, about 19 words

    See this version in full on ClinicalTrials.gov ↗

  9. Study sites: 33 to 38v14
  10. Primary completion date: Dec 2022 to Jun 2024 Study sites: 30 to 33 · Eligibility criteria expanded, about 98 words · Secondary endpoints: details revised at 3 of 8 entries · 1 morev13 Show 4 more changesShow less
    • Study sites: 30 to 33
    • Eligibility criteria expanded, about 98 words
    • Secondary endpoints: details revised at 3 of 8 entries
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  11. Study sites: 22 to 30v12
  12. Study sites: 17 to 22v11
  13. Study sites: 15 to 17v10
  14. Study sites: 11 to 15v9
  15. Study sites: 10 to 11 Start date changed from estimate of Apr 2021 to May 7, 2021v8 Show 1 more changeShow less
    • Start date changed from estimate of Apr 2021 to May 7, 2021
  16. Study sites: 5 to 10 Start date: Mar 2021 to Apr 2021v7 Show 1 more changeShow less
    • Start date: Mar 2021 to Apr 2021
  17. Study sites: 4 to 5 Start date: Feb 2021 to Mar 2021v6 Show 1 more changeShow less
    • Start date: Feb 2021 to Mar 2021
  18. Study sites: 3 to 4 Start date: Jan 2021 to Feb 2021v5 Show 1 more changeShow less
    • Start date: Jan 2021 to Feb 2021
  19. Study sites: 2 to 3v4
  20. Start date: Nov 2020 to Jan 2021 Study sites: 1 to 2v3 Show 1 more changeShow less
    • Study sites: 1 to 2
  21. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Trial Details
NCT Number NCT04614103
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Metastatic Non Small Cell Lung Cancer
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov